Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211986 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
A Phase 1 study of Muscle Atrophy, sponsored by Immunis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05211986 is a Phase 1 study of Muscle Atrophy that is actively recruiting participants, run by Immunis. The registered enrollment target is 28 participants, below the 47-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05211986, a Phase 1 study of Muscle Atrophy, is actively recruiting participants, sponsored by Immunis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis
Conditions Studied
Interventions
- DRUG IMM01-STEM
Study Locations (2)
California
- Orthopaedic Specialty Institute - Irvine
- University of California, Irvine - Alpha Stem Cell Clinic - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05211986
The ClinicalTrials.gov registry entry for NCT05211986 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (40% lower). The listed sponsor is Immunis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle Atrophy appearing as the primary indexed condition, and to 1 intervention - of which IMM01-STEM is the first listed.
NCT05211986 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05211986 about?
NCT05211986 is a clinical study titled "Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.". An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis
What is the current status of trial NCT05211986?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-09-13. Estimated completion is 2026-06-30.
What conditions does trial NCT05211986 study?
This clinical trial studies the following conditions: Muscle Atrophy.
What interventions are being tested in trial NCT05211986?
The interventions under investigation include: IMM01-STEM (DRUG).
Who is sponsoring clinical trial NCT05211986?
This trial is sponsored by Immunis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05211986 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Electrical Stimulation for Critically Ill Covid-19 Patients
COMPLETED · Phase 1
-
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
RECRUITING
-
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
RECRUITING · NA
-
A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
-
Essential Amino Acid Supplementation for Femoral Fragility Fractures
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.